IPH 4102

Drug Profile

IPH 4102

Alternative Names: Anti-KIR3DL2 cytotoxic mAb; IPH 41 programme; IPH 4101; IPH41; IPH4102

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator University of Genoa
  • Developer Innate Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action KIR receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous T cell lymphoma

Most Recent Events

  • 26 Oct 2016 Preliminary efficacy, pharmacodynamics and adverse events data from a phase I trial in Cutaneous T-cell lymphoma (Second-line therapy or greater) released by Innate Pharma
  • 29 Oct 2015 Phase-I clinical trials in Cutaneous T-cell lymphoma (Second-line therapy or greater) in France (IV)
  • 17 Sep 2015 Innate Pharma plans a phase I trial for Cutaneous T-cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top